Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous RAG1 lentiviral CD34+ stem cell gene therapy for RAG1-deficient SCID
NL-OMON54570Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2021
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RAG1 LV CD34+ autologous hematopoietic stem cells in severe combined immunodeficiency (SCID), sponsored by Leiden University Medical Center. Primary endpoints: Feasibility and Event-free survival. Started Jul 2021; status: recruiting.
02
Drugs
RAG1 LV CD34+ autologous hematopoietic stem cells
03
Conditions
severe combined immunodeficiency (SCID)
Beyond the preview
Go deeper on NL-OMON54570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54570.